Theravance Biopharma (TBPH) Tops Q3 EPS by 19c

Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($0.73), $0.19 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $19.1 million versus the consensus estimate of $12.62 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• B. Riley previews Semi Cap Equipment sector ahead of Semicon West
• General Mills posts lower Q1 sales, reaffirms fiscal 2027 targets